SEC Company Response from Vanda Pharmaceuticals (VNDA) — Jul 17, 2015
Vanda Pharmaceuticals Inc.
Date: July 17, 2015 · CIK: 0001347178 · Accession: 0001193125-15-256000
AI Filing Summary & Sentiment
File numbers found in text: 333-205513
Letter
VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Washington, D.C. 20549 Attn: Alla Berenshteyna Re: Vanda Pharmaceuticals Inc. Registration Statement on Form S-3 (File No. 333-205513)
Dear Ms. Berenshteyna:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Vanda Pharmaceuticals Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-referenced Registration Statement on Form S-3 effective at 4:30 p.m. Eastern Time on Tuesday, July 21, 2015 or as soon thereafter as practicable.
The Company hereby acknowledges that:
•
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
The Company hereby authorizes Gregg Griner of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, counsel to the Company, to orally modify or withdraw this request for acceleration.
Please provide a copy of the Commission’s order declaring the Registration Statement effective to Gregg Griner at Gunderson Dettmer, One Marina Park Drive, Suite 900, Boston, MA 02210. If possible, please also send such order by email to the attention of Gregg Griner at ggriner@gunder.com.
Thank you for your attention on this matter.
Very truly yours,
Vanda Pharmaceuticals Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Vanda Pharmaceuticals Inc. 2200 Pennsylvania Avenue NW Suite 300E Washington, DC 20037 July 17, 2015 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street N.E. Washington, D.C. 20549 Attn: Alla Berenshteyna Re: Vanda Pharmaceuticals Inc. Registration Statement on Form S-3 (File No. 333-205513) Dear Ms. Berenshteyna: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Vanda Pharmaceuticals Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-referenced Registration Statement on Form S-3 effective at 4:30 p.m. Eastern Time on Tuesday, July 21, 2015 or as soon thereafter as practicable. The Company hereby acknowledges that: • should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; • the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. The Company hereby authorizes Gregg Griner of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, counsel to the Company, to orally modify or withdraw this request for acceleration. Please provide a copy of the Commission’s order declaring the Registration Statement effective to Gregg Griner at Gunderson Dettmer, One Marina Park Drive, Suite 900, Boston, MA 02210. If possible, please also send such order by email to the attention of Gregg Griner at ggriner@gunder.com. Thank you for your attention on this matter. Very truly yours, Vanda Pharmaceuticals Inc. By: /s/ James P. Kelly James P. Kelly Chief Financial Officer cc: Gregg Griner, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP Albert Vanderlaan, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP